ARMPArmata Pharmaceuticals Inc
$7.80
$0.33
(4.42%)
Reported EarningsMay 13
Mkt Cap$274.23M
Vol11,310.00
Fundamentals
Mkt Cap
$274.23M
Volume
-
52W High
$16.34
52W Low
$1.74
PE Ratio
-0.96
Avg. Volume
80,453.38
EPS (Annual)
-$4.80
Rev/Employee
$80,393.44
Earnings
May 13
40
Bearish Sentiment
How do you feel about ARMP?
Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update
Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update PR Newswire LOS...
PR Newswire
Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02
Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02 Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02 PR Newswire LOS ANGELES, May 7, 2026 Enables more frequent...
PR Newswire
Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"
Armata Pharmaceuticals Announces Structural Biology Publication in 'Communications Biology' Armata Pharmaceuticals Announces Structural Biology Publication in 'Communications Biology' PR Newswire LOS...
PR Newswire
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results PR Newswire LOS ANGELES...
PR Newswire
Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update
Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025...
PR Newswire
Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02
Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02 Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for...
PR Newswire
Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus
Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus Armata Pharmaceuticals...
PR Newswire
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates
Armata Pharmaceuticals (ARMP) delivered earnings and revenue surprises of 0.00% and -16.01%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Agenus (AGEN) Misses Q3 Earnings and Revenue Estimates
Agenus (AGEN) delivered earnings and revenue surprises of -26.24% and -71.95%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates
Coherus Oncology (CHRS) delivered earnings and revenue surprises of -3.13% and -5.23%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
<
1
2
...
>
Advertisement|Remove ads.
Latest ARMP News
ViewArmata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update
PR Newswire
Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02
PR Newswire
Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"
PR Newswire
Advertisement|Remove ads.